|
Investor Relations in a biotechnology company
Living Cell Technologies is a fast growing public bioscience company listed on the
Australian Stock Exchange
with over 1200 shareholders from Australasia, Europe and the United States of America.
The
company is very product driven building an international entity that
will have its own capabilities of providing
live cell therapies in Asia Pacific, USA and Europe.
Stock Price (ASX)
5/14/2008 -
8:08pm
|
|---|
| code: | LCT |
| last: | 0.300 |
| change: | 0.000 |
LCT American Depositary Receipts (ADR's)
LCT shares trade in the USA under the symbol 'LVCLY'
LCT has established a Level 1 American Depositary Receipt (ADR) program in the US.
The ADR program facilitates the purchase of LCT stock in the over-the counter (OTC)
pink sheet market (www.pinksheets.com) by US investors.The program became effective
on 17 July 2007 and the Company's ADR's are traded over-the-counter under the symbol 'LVCLY'.
LCT's American Depositary Shares (ADSs) will trade on a 1:10 ratio to the Company's ordinary
shares, which are listed on the Australian Stock Exchange under the symbol LCT.
An ADR Program enables companies based outside of the US to participate in the US capital
markets. It enables private investors and institutions to purchase LCT shares, including
investors only permitted to buy US based securities.
The Bank of New York, which has significant experience in bringing quality Australian and
other issuers to the US market and promoting ADR's as an effective capital markets tool,
has been appointed as the Company's depositary bank.
Where are LCT ADRs traded and under what ticker?
Symbol LVCLY
CUSIP 53838R107
Exchange OTC
Ratio 1 ADR: 10 ORDs
Depositary BoNY
Effective Date 17 July 2007
US ISIN US53838R1077
About ADRs
How to purchase ADRs
ADR Frequently Asked Questions
Mailing Address
PO Box 3014
Auburn VIC 3123
Australia
Investor relations inquiries
| 
